On December 23, 2019 Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) reported that it will host an investor event to discuss expected corporate and product milestones in 2020 (Press release, Portola Pharmaceuticals, DEC 23, 2019, https://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-webcast-corporate-update-on-january-14-2020-300978499.html [SID1234552597]). The event is scheduled to take place on Tuesday, January 14, at 7 a.m. PT (10 a.m. ET) and will be simultaneously webcast.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Portola will provide updates on Andexxa and Ondexxya and its investigational hematologic compound, the oral SYK/JAK inhibitor cerdulatinib.

Webcast Details
To access the live investor webcast on Tuesday, January 14, at 7 a.m. PT (10 a.m. ET), go to the investor section of the company’s website at View Source A replay will be available for 30 days.